As of 2026-10-17, the EV/EBITDA ratio of Relay Therapeutics Inc (RLAY) is -10.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RLAY's latest enterprise value is 3,388.13 mil USD. RLAY's TTM EBITDA according to its financial statements is -311.18 mil USD. Dividing these 2 quantities gives us the above RLAY EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.4x - 17.3x | 14.4x |
| Forward P/E multiples | 17.0x - 30.3x | 18.4x |
| Fair Price | (23.98) - (24.47) | (23.04) |
| Upside | -247.3% - -250.3% | -241.5% |
| Date | EV/EBITDA |
| 2026-10-15 | -11.59 |
| 2026-10-14 | -11.43 |
| 2026-10-13 | -11.64 |
| 2026-10-12 | -12.07 |
| 2026-10-09 | -12.00 |
| 2026-10-08 | -11.67 |
| 2026-10-07 | -12.05 |
| 2026-10-06 | -12.59 |
| 2026-10-05 | -13.04 |
| 2026-10-02 | -12.74 |
| 2026-10-01 | -12.42 |
| 2026-09-30 | -12.11 |
| 2026-09-29 | -12.33 |
| 2026-09-28 | -11.86 |
| 2026-09-25 | -11.71 |
| 2026-09-24 | -11.89 |
| 2026-09-23 | -12.10 |
| 2026-09-22 | -13.01 |
| 2026-09-21 | -12.21 |
| 2026-09-18 | -12.66 |
| 2026-09-17 | -12.90 |
| 2026-09-16 | -12.66 |
| 2026-09-15 | -12.75 |
| 2026-09-14 | -12.81 |
| 2026-09-11 | -12.68 |
| 2026-09-10 | -12.70 |
| 2026-09-09 | -12.54 |
| 2026-09-08 | -12.85 |
| 2026-09-04 | -12.80 |
| 2026-09-03 | -12.78 |
| 2026-09-02 | -12.43 |
| 2026-09-01 | -12.42 |
| 2026-08-31 | -12.34 |
| 2026-08-28 | -12.61 |
| 2026-08-27 | -13.06 |
| 2026-08-26 | -13.09 |
| 2026-08-25 | -13.86 |
| 2026-08-24 | -13.30 |
| 2026-08-21 | -13.08 |
| 2026-08-20 | -13.26 |
| 2026-08-19 | -13.98 |
| 2026-08-18 | -13.89 |
| 2026-08-17 | -13.93 |
| 2026-08-14 | -13.37 |
| 2026-08-13 | -13.42 |
| 2026-08-12 | -13.51 |
| 2026-08-11 | -13.46 |
| 2026-08-10 | -13.42 |
| 2026-08-07 | -13.31 |
| 2026-08-06 | -13.29 |